This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Tylvalosin
- DrugBank Accession Number
- DB11554
- Background
Not Available
- Type
- Small Molecule
- Groups
- Vet approved
- Structure
Structure for Tylvalosin (DB11554)
- Weight
- Average: 1042.267
Monoisotopic: 1041.587229585 - Chemical Formula
- C53H87NO19
- Synonyms
- Tylvalosin
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Tylvalosin. Acetyldigitoxin The serum concentration of Acetyldigitoxin can be increased when it is combined with Tylvalosin. Alfentanil The serum concentration of Alfentanil can be increased when it is combined with Tylvalosin. Alprazolam The serum concentration of Alprazolam can be increased when it is combined with Tylvalosin. Ambroxol The risk or severity of methemoglobinemia can be increased when Tylvalosin is combined with Ambroxol. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Tylvalosin tartrate AL5667FY0W 63428-13-7 OLLSDNUHBJHKJS-XKORHJEPSA-N - International/Other Brands
- Aivlosin
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as aminoglycosides. These are molecules or a portion of a molecule composed of amino-modified sugars.
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Carbohydrates and carbohydrate conjugates
- Direct Parent
- Aminoglycosides
- Alternative Parents
- Macrolides and analogues / Disaccharides / O-glycosyl compounds / Tricarboxylic acids and derivatives / Fatty acid esters / Oxanes / Alpha-hydrogen aldehydes / Tertiary alcohols / 1,2-aminoalcohols / Trialkylamines show 11 more
- Substituents
- 1,2-aminoalcohol / Acetal / Alcohol / Aldehyde / Aliphatic heteromonocyclic compound / Alpha-hydrogen aldehyde / Amine / Amino acid or derivatives / Aminoglycoside core / Carbonyl group show 26 more
- Molecular Framework
- Aliphatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 9T02S42WQO
- CAS number
- 63409-12-1
- InChI Key
- KCJJINQANFZSAM-HZDSEHBESA-N
- InChI
- InChI=1S/C53H87NO19/c1-16-38-36(26-65-52-49(64-15)48(63-14)44(60)31(7)67-52)22-28(4)17-18-37(57)29(5)23-35(19-20-55)46(30(6)39(69-34(10)56)24-41(59)70-38)73-51-45(61)43(54(12)13)47(32(8)68-51)72-42-25-53(11,62)50(33(9)66-42)71-40(58)21-27(2)3/h17-18,20,22,27,29-33,35-36,38-39,42-52,60-62H,16,19,21,23-26H2,1-15H3/b18-17+,28-22+/t29-,30+,31-,32-,33+,35+,36-,38-,39-,42+,43-,44-,45-,46-,47-,48-,49-,50+,51+,52-,53-/m1/s1
- IUPAC Name
- (2S,3S,4R,6S)-6-{[(2R,3S,4R,5R,6R)-6-{[(4R,5S,6S,7R,9R,11E,13E,15R,16R)-4-(acetyloxy)-16-ethyl-15-({[(2R,3R,4R,5R,6R)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxy}methyl)-5,9,13-trimethyl-2,10-dioxo-7-(2-oxoethyl)-1-oxacyclohexadeca-11,13-dien-6-yl]oxy}-4-(dimethylamino)-5-hydroxy-2-methyloxan-3-yl]oxy}-4-hydroxy-2,4-dimethyloxan-3-yl 3-methylbutanoate
- SMILES
- CC[C@H]1OC(=O)C[C@@H](OC(C)=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(\C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC
References
- General References
- Guedes RM, Franca SA, Machado GS, Blumer MA, da Costa Cruz EC Jr: Use of tylvalosin-medicated feed to control porcine proliferative enteropathy. Vet Rec. 2009 Sep 19;165(12):342-5. [Article]
- Forrester CA, Bradbury JM, Dare CM, Domangue RJ, Windsor H, Tasker JB, Mockett AP: Mycoplasma gallisepticum in pheasants and the efficacy of tylvalosin to treat the disease. Avian Pathol. 2011 Dec;40(6):581-6. doi: 10.1080/03079457.2011.618822. [Article]
- Cerda RO, Petruccelli M, Piscopo M, Origlia J, Landoni M: Impact of the type of catheter on the absorption of tylvalosin (acetylvaleryltylosin) administered orally to broiler chickens. J Vet Pharmacol Ther. 2010 Apr;33(2):202-3. doi: 10.1111/j.1365-2885.2009.01103.x. [Article]
- Garces-Narro C, Barragan JI, Soler MD, Mateos M, Lopez-Mendoza MC, Homedes J: Efficacy of low-dose tylvalosin for the control of clostridiosis in broilers and its effect on productive parameters. Poult Sci. 2013 Apr;92(4):975-8. doi: 10.3382/ps.2012-02750. [Article]
- Bohm DA, Stachel CS, Gowik P: Validation of a multi-residue method for the determination of several antibiotic groups in honey by LC-MS/MS. Anal Bioanal Chem. 2012 Jul;403(10):2943-53. doi: 10.1007/s00216-012-5868-z. Epub 2012 Feb 26. [Article]
- Svartstrom O, Karlsson F, Fellstrom C, Pringle M: Characterization of Treponema spp. isolates from pigs with ear necrosis and shoulder ulcers. Vet Microbiol. 2013 Oct 25;166(3-4):617-23. doi: 10.1016/j.vetmic.2013.07.005. Epub 2013 Jul 17. [Article]
- Duinhof TF, Dierikx CM, Koene MG, van Bergen MA, Mevius DJ, Veldman KT, van Beers-Schreurs HM, de Winne RT: [Multiresistant Brachyspira hyodysenteriae in a Dutch sow herd]. Tijdschr Diergeneeskd. 2008 Jul 15-Aug 1;133(14-15):604-8. [Article]
- Hidalgo A, Carvajal A, Vester B, Pringle M, Naharro G, Rubio P: Trends towards lower antimicrobial susceptibility and characterization of acquired resistance among clinical isolates of Brachyspira hyodysenteriae in Spain. Antimicrob Agents Chemother. 2011 Jul;55(7):3330-7. doi: 10.1128/AAC.01749-10. Epub 2011 May 9. [Article]
- Pringle M, Landen A, Unnerstad HE, Molander B, Bengtsson B: Antimicrobial susceptibility of porcine Brachyspira hyodysenteriae and Brachyspira pilosicoli isolated in Sweden between 1990 and 2010. Acta Vet Scand. 2012 Sep 21;54:54. doi: 10.1186/1751-0147-54-54. [Article]
- Tavio MM, Poveda C, Assuncao P, Ramirez AS, Poveda JB: In vitro activity of tylvalosin against Spanish field strains of Mycoplasma hyopneumoniae. Vet Rec. 2014 Nov 29;175(21):539. doi: 10.1136/vr.102458. Epub 2014 Sep 2. [Article]
- External Links
- ChemSpider
- 4945313
- 1368469
- ChEMBL
- CHEMBL2103834
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Powder Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0361 mg/mL ALOGPS logP 3.8 ALOGPS logP 4.63 Chemaxon logS -4.5 ALOGPS pKa (Strongest Acidic) 12.57 Chemaxon pKa (Strongest Basic) 8.43 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 17 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 250.81 Å2 Chemaxon Rotatable Bond Count 19 Chemaxon Refractivity 264.29 m3·mol-1 Chemaxon Polarizability 111.37 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at February 26, 2016 17:46 / Updated at April 21, 2021 06:20